TheraRadar

Pharma Intelligence, Simplified

Landscape → Ophthalmology

Dry Eye

330 clinical trials

60 active
/
330 total (since 2015)
8
Phase 1 Active
42 total
18
Phase 2 Active
116 total
10
Phase 3 Active
95 total
27
Phase 4 Active
107 total

Top Sponsors (Industry)

Sorted by active Active Done Failed
AbbVie 2 7 2
Laboratorios Sophia S.A de C.V. 2 9 0
Bausch & Lomb Incorporated 2 7 1
Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. 2 2 0
IVIEW Therapeutics Inc. 2 1 0
Vanda Pharmaceuticals 2 0 0
BRIM Biotechnology Inc. 1 3 0
ORA, Inc. 1 3 0
Cambium Bio Limited 1 1 0
VivaVision Biotech, Inc 1 1 0
Azura Ophthalmics 1 1 0
Telios Pharma, Inc. 1 1 0
AJU Pharm Co., Ltd. 1 1 0
Instituto Grifols, S.A. 1 0 0
Laboratoires Thea 1 0 0
NCT07284381 RECRUITING
A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear Formulation (ABBV-444) Compared to Refresh Optive Unit Dose in Adult Participants With Dry Eye Disease
AbbVie n=250
NCT06766357 RECRUITING
A Study of the Efficacy and Safety of Cyclosporin Ophthalmic Gel in Subjects With Moderate to Severe Dry Eye Disease
Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. n=360
NCT06903611 NOT YET RECRUITING
Phase III Study of Topical Fibrinogen-Depleted Human Platelet Lysate Compared to Placebo for Moderate to Severe Dry Eye
Cambium Bio Limited n=400
NCT06942793 NOT YET RECRUITING
A Study to Evaluate the Efficacy and Safety of Treatment With CsA-PG Ophthalmic Gel in Dry Eye Patients
Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. n=396
NCT06931041 ACTIVE NOT RECRUITING
Comparing Efficacy of Autologous Serum Eye Drops With and Without Insulin in Autoimmune Dry Eye: A Randomized Clinical Trial
Instituto de Oftalmología Fundación Conde de Valenciana n=25
NCT06879782 RECRUITING
Phase III Clinical Study of Lifitegrast Ophthalmic Solution for the Treatment of Dry Eye Disease
Lunan Better Pharmaceutical Co., LTD. n=820
NCT06360133 RECRUITING
Study of 5% VVN001 Ophthalmic Solution in Dry Eye Disease
VivaVision Biotech, Inc n=700
NCT06329791 ACTIVE NOT RECRUITING
A Phase 3 Study to Evaluate AZR-MD-001 in Patients with Abnormal Meibomian Gland Function and Dry Eye Disease (DED)
Azura Ophthalmics n=500
NCT06392438 RECRUITING
Cyclosporine and Intense Pulsed Light for Dry Eye in Contact Lens Users
Université de Sherbrooke n=44
NCT06291194 RECRUITING
Efficacy and Safety of AJU-S56 5% in Dry Eye Syndrome Patients
AJU Pharm Co., Ltd. n=396
NCT06388070 COMPLETED
To Evaluate the Efficacy and Safety of HUC3-053 in Patients With Dry Eye Syndrome
Huons Co., Ltd. n=297
NCT06544707 COMPLETED
A Study Designed to Evaluate Tear Production
Alcon Research n=81
NCT05411367 COMPLETED
A Study for Evaluation of the Efficacy and Safety of SI-614 Ophthalmic Solution in Patient With Dry Eye
Seikagaku Corporation n=232
NCT06493604 COMPLETED
A Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease
Aldeyra Therapeutics, Inc. n=116
NCT07111013 WITHDRAWN
A Study to Assess the Long-Term Safety of Lifitegrast/Perfluorohexyloctane Fixed-Dose Combination in Subjects With Dry Eye Disease
Bausch & Lomb Incorporated
NCT05136170 COMPLETED
Study to Evaluate Safety and Efficacy of Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease
Dompé Farmaceutici S.p.A n=85
NCT04735393 COMPLETED
A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Clinical Trial Evaluating the Safety of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease
Aldeyra Therapeutics, Inc. n=757
NCT06717152 COMPLETED
Efficacy and Safety of SJP-0132 Eye Drops in Chinese Patients With Dry Eye Disease
Senju Pharmaceutical Science & Technology (Beijing) Co., Ltd. n=427
NCT06424444 COMPLETED
A Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease
Aldeyra Therapeutics, Inc. n=421
NCT05493111 COMPLETED
A Long-Term Safety Study Evaluating the Safety and Systemic Exposure of AR-15512
Aerie Pharmaceuticals n=275
NCT06544694 COMPLETED
A Study to Investigate the Effect of 0.003% AR-15512 on Subjects With Dry Eye Disease
Alcon Research n=79
NCT05285644 COMPLETED
Study Evaluating the Safety and Efficacy of AR-15512
Aerie Pharmaceuticals n=465
NCT05360966 COMPLETED
Study Evaluating the Safety and Efficacy of AR-15512 (COMET-3)
Aerie Pharmaceuticals n=467
NCT07050446 COMPLETED
Vizol S DIGI EYE Efficacy and Safety Study in Patients With Dry Eye
Jadran Galenski laboratorij d.d. n=86
NCT06389214 COMPLETED
A Clinical Trial to Assess the Efficacy and Safety of Subjects With Dry Eye Disease
Aldeyra Therapeutics, Inc. n=132
NCT06427031 COMPLETED
Comparing Efficacy and Safety of TJO-083 in Dry Eye Diseases Patients
Taejoon Pharmaceutical Co., Ltd. n=271
NCT04674358 COMPLETED
The TRANQUILITY Trial: Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease
Aldeyra Therapeutics, Inc. n=329
NCT05062330 COMPLETED
The TRANQUILITY 2 Trial: A Phase 3 Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease
Aldeyra Therapeutics, Inc. n=361
NCT06660290 COMPLETED
A Study to Evaluate 0.003% AR-15512 Safety and Drop Attributes
Alcon Research n=55
NCT03879863 COMPLETED
The RENEW Trial: A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Adaptive Phase 3 Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease
Aldeyra Therapeutics, Inc. n=422
NCT05403827 COMPLETED
A Study to Confirm the Efficacy and Safety of K-161 Ophthalmic Solution for Treatment of Moderate to Severe Dry Eye Disease
Kowa Research Institute, Inc. n=644
NCT04139798 COMPLETED
Perfluorohexylcotane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Gobi Study)
Bausch & Lomb Incorporated n=599
NCT05201170 COMPLETED
A Phase 3, Multi-Center Study Evaluating PL9643 in Patients with Dry Eye
Palatin Technologies, Inc n=575
NCT05878067 COMPLETED
A Study to Assess Symptom Relief and Product Tolerability of ABBV-444 Drops in Adult Participants
AbbVie n=40
NCT05743764 COMPLETED
HU007 in Patients with Dry Eye Syndrome
Huons Co., Ltd. n=328
NCT04144413 COMPLETED
3-year Study in Dry Eye Disease Patients With Severe Keratitis Receiving Ikervis® (1mg/mL Ciclosporin)
Santen SAS n=350
NCT04567329 COMPLETED
Effect of NOV03 on Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Mojave Study)
Bausch & Lomb Incorporated n=620
NCT04181593 COMPLETED
Phase 3 Study of the Safety and Efficacy of OmegaD Softgels in the Treatment of Dry Eye Disease
OmegaD LLC n=322
NCT06517667 COMPLETED
Efficacy and Safety of Different Hyaluronic Acid Tear Substitutes Formulations in Evaporative Dry Eye
University of Seville n=30
NCT05695781 COMPLETED
Assessment of the Safety and Efficacy of BRM421 Ophthalmic Solutions in Dry Eye Subjects.
BRIM Biotechnology Inc. n=740
NCT06478134 COMPLETED
Efficacy and Safety of a Multiple-Action Tear Substitute (TriMix) in Dry Eye Disease
University of Seville n=124
NCT04393441 COMPLETED
Efficacy and Safety of a New Artificial Tear Formulation Compared With Systane Ultra Multidose in Participants With Dry Eye Disease
Allergan n=400
NCT05848128 COMPLETED
Efficacy and Safety Evaluation of Tavilermide Ophthalmic Solution for the Treatment of Dry Eye
Mimetogen Pharmaceuticals USA, Inc. n=642
NCT05133180 COMPLETED
Safety and Efficacy Study on Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease (PROTEGO-1 Study)
Dompé Farmaceutici S.p.A n=104
NCT06400589 SUSPENDED
A Study to Evaluate the Efficacy and Safety of Tanfanercept (HL036) in Dry Eye Disease
HanAll BioPharma Co., Ltd. n=750
NCT06323395 COMPLETED
Vizol S Lipid Balance Efficacy and Safety Study in Patients With Dry Eye
Jadran Galenski laboratorij d.d. n=64
NCT04140227 COMPLETED
Long-Term Safety and Tolerability of NOV03 (Perfluorohexyloctane) in Subjects Who Completed Trial NVU-003 (Kalahari Study)
Bausch & Lomb Incorporated n=256
NCT04819269 COMPLETED
Tivanisiran for Dry Eye in Subjects With Sjögren's Syndrome
Sylentis, S.A. n=203
NCT05310422 COMPLETED
Safety Study of Tivanisiran to Treat Dry Eye
Sylentis, S.A. n=301
NCT03920215 COMPLETED
Evaluation of the Long Term Follow up of the Efficacy of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease
Oyster Point Pharma, Inc. n=101
NCT05109702 COMPLETED
A Study to Assess the Efficacy and Safety of Tanfanercept (HL036) Ophthalmic Solution in Participants With Dry Eye
HanAll BioPharma Co., Ltd. n=260
NCT04683796 COMPLETED
Comparison of Efficacy Between 100% Platelet-rich Plasma and 100% Serum Eye Drops in Dry Eye Disease
Mahidol University n=96
NCT04523142 COMPLETED
CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease in Subjects Who Completed CYS-004
Novaliq GmbH n=202
NCT05082974 COMPLETED
Investigator Initiated Study to Assess the Efficacy of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease Following Laser-assisted in Situ Keratomileusis (LASIK)
Vance Thompson Vision ND n=40
NCT05841043 COMPLETED
Efficacy and Safety of SHR8028 Eye Drops for the Treatment of Dry Eye Disease
Jiangsu HengRui Medicine Co., Ltd. n=206
NCT05378945 COMPLETED
Clinical Trial to Evaluate the Efficacy and Safety of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease
Corxel Pharmaceuticals n=340
NCT03925727 COMPLETED
Tavilermide Ophthalmic Solution for the Treatment of Dry Eye
Mimetogen Pharmaceuticals USA, Inc. n=623
NCT04899518 COMPLETED
ALY688 Ophthalmic Solution in Subjects With Dry Eye Disease
Allysta Pharmaceutical n=922
NCT04523129 COMPLETED
ESSENCE 2: CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)
Novaliq GmbH n=834
NCT05027087 COMPLETED
The Effect of a Novel Blueberry Supplement on Dry Eye Disease
SightSage Foods and Nutrition Inc. n=68
NCT05322148 COMPLETED
Cyclosporine 0.1% / Loteprednol 0.2% Effect on Anterior Segment Normalization
Research Insight LLC n=59
NCT03292809 COMPLETED
CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)
Novaliq GmbH n=328
NCT05598242 COMPLETED
Amniotic Membrane Treatment for Hyposecretory Dry Eye
Hospital Nacional Profesor Alejandro Posadas n=37
NCT05515471 COMPLETED
Effect of SHR8058 on Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction
Jiangsu HengRui Medicine Co., Ltd. n=312
NCT03785340 COMPLETED
Study of Brimonidine Tartrate Nanoemulsion Eye Drop Solution in the Treatment of Dry Eye Disease (DED)
Ocugen n=252
NCT04670263 COMPLETED
Evaluating the Efficacy of Dry Eye (DE) Disease Treatment Using Novel Tear Film Imager (TFI)
Adom Advanced Optical Technologies Ltd. n=70
NCT05425914 COMPLETED
Impact of Vitamin D3 Supplementation in Non-Sjogren Dry Eye Patients With Low Serum Vitamin D Level
University of Faisalabad n=108
NCT03937882 COMPLETED
Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-3
ReGenTree, LLC n=700
NCT04541888 COMPLETED
Assess the Safety and Efficacy of CsA Ophthalmic Gel in Subjects With Moderate to Severe Dry Eye Disease
Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. n=644
NCT03846453 COMPLETED
A Study to Assess Efficacy and Safety of HL036 in Subjects With Dry Eyes
HanAll BioPharma Co., Ltd. n=637
NCT03764735 COMPLETED
Study of SkQ1 as Treatment for Dry-eye Syndrome
Mitotech, SA n=452
NCT04206020 COMPLETED
Vehicle-Controlled Study of SkQ1 as Treatment for Dry-eye Syndrome
Mitotech, SA n=610
NCT02974907 COMPLETED
Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome : ARISE-2
ReGenTree, LLC n=601
NCT04147650 COMPLETED
Dose Ranging Study to Assess the Efficacy and Safety of Voclosporin Ophthalmic Solution in Subjects With Dry Eye Syndrome
Aurinia Pharmaceuticals Inc. n=508
NCT04036292 COMPLETED
Evaluation of the Efficacy and Safety of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease
Oyster Point Pharma, Inc. n=758
NCT04343287 COMPLETED
Safety and Efficacy of BRM421 for Dry Eye Syndrome Treatment
BRIM Biotechnology Inc. n=220
NCT05017844 COMPLETED
[KSR-001-P02] Phase 2b/3 Study, Evaluate the Efficacy and Safety of KSR-001 in Patients With Dry Eye Syndrome
Kukje Pharma n=222
NCT04548427 COMPLETED
Study to Evaluate the Efficacy and Safety of CKD-352
Chong Kun Dang Pharmaceutical n=283
NCT02813265 COMPLETED
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
Kala Pharmaceuticals, Inc. n=918
NCT04714099 COMPLETED
Topical Cyclosporine A for the Treatment of Dry Eye: A Randomized Clinical Study
Alexandria University n=40
NCT02819284 COMPLETED
Safety and Efficacy of KPI-121 Compared to Placebo in Subjects With Dry Eye Disease
Kala Pharmaceuticals, Inc. n=909
NCT04384991 COMPLETED
HU007 Eye Drops in Patients With Dry Eye Syndrome
Huons Co., Ltd. n=216
NCT02871440 COMPLETED
A Two Comparator, Controlled Phase 3 Study in Patients With and Without Evaporative Dry Eye
The University of New South Wales n=40
NCT03461575 COMPLETED
Efficacy and Safety of HU007 Eye Drops in Patients With Dry Eye Syndrome
Huons Co., Ltd. n=209
NCT02980224 COMPLETED
Study of the Safety and Efficacy of OmegaD Softgels in the Treatment of Dry Eye Disease
OmegaD LLC n=180
NCT02701764 COMPLETED
Can Pregabalin Reduce the Frequency and Severity of Dry Eye Symptoms After Laser-assisted in Situ Keratomileusis?
University of Miami n=43
NCT02597803 COMPLETED
Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-1
ReGenTree, LLC n=317
NCT03833388 COMPLETED
Study of TOP1630 for Dry Eye Syndrome
Topivert Pharma Ltd n=202
NCT03518398 COMPLETED
Effectiveness and Safety of Intense Pulsed Light in Patients With Meibomian Gland Dysfunction
Chulalongkorn University n=114
NCT03865888 COMPLETED
Comparing Effect of Topical Tacrolimus 0.03% Versus Cyclosporine 0.05% in Dry Eyes of Secondary Sjogren Syndrome
Pavly Moawd n=60
NCT03527212 COMPLETED
A Study to Assess the Safety and Effectiveness of SJP-0035 for the Treatment of Patients With Dry Eye Disease
Senju Pharmaceutical Co., Ltd. n=329
NCT02815293 TERMINATED
Topical Ophthalmic AGN-195263 for the Treatment of Evaporative Dry Eye
Allergan n=36
NCT03108664 COMPLETED
HELIX, a Double-masked Study of SYL1001 in Patients With Moderate to Severe Dry Eye Disease (DED)
Sylentis, S.A. n=330
NCT02965846 TERMINATED
Topical Ophthalmic AGN-195263 for the Treatment of Evaporative Dry Eye
Allergan n=43
NCT02553772 COMPLETED
A Safety and Efficacy Study of a New Eye Drop Formulation in Patients With Dry Eye Disease.
Allergan n=242

Data: ClinicalTrials.gov